Survival curves of pediatric AMKL patients. The 4-year pEFS (A), 4-year pOS (B), and 4-year pCIR (C) comparing the outcome of patients of the different enrolled study groups. There is no significant difference in outcome among the study groups. The 4-year pEFS (D), 4-year pOS (E), and 4-year pCIR (F) comparing the described cytogenetic subgroups as identified in pediatric non-Down syndrome AMKL. RBM15/MKL1-positive cases and other pediatric AMKL have a favorable outcome compared with NUP98/KDM5A, CBFA2T3/GLIS, KMT2A rearrangements and monosomy 7 cases. The 4-year pEFS (G), 4-year pOS (H), and 4-year pCIR (I) of the NUP98/KDM5A, CBFA2T3/GLIS2, KMT2A rearrangements and monosomy 7 cases compared with the RBM15/MKL1 and other pediatric AMKL cases. Harboring NUP98/KDM5A, CBFA2T3/GLIS2, KMT2A rearrangements or monosomy 7 confers a poor outcome.